Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The aim of the trial is to optimize response rates and rates of secondary resections of
metastases in patients with initially non-resectable metastatic colorectal cancer Liver
Metastasis of RAS wildtype. The patients will be treated in two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI + Cetuximab Standard arm B: Chemotherapy with
FOLFOX + Cetuximab